Trial reportEye (London, England)2026
Evaluating the effect of a new myopia control spectacle lens among children in Israel: 24-month results.
Trial report in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the effectiveness of a novel spectacle lens designed to slow the progression of myopia in children.
methodsIn this prospective clinical trial, children aged 6-13 years (N = 126) with spherical equivalent (SER) refractive errors of -0.5 to -6.25 dioptres (D) were randomised into either the Shamir Myopia Control (SMC) lens group or single-vision spectacle lenses (SVL) groups. Outcome measures were changes in axial length (AL), SER, and subjective rating of visual experience (SVE).
resultsAfter 24 months, AL elongation in the SMC group (N:38) was slowed by 33%, while SER progression was slowed by 26% compared to SVL (N:37, p < 0.05). In the SMC younger subgroup (6-10 years), AL elongation was slowed by 0.28 mm (44%, p < 0.001) while SER progression was slowed by 0.53 D (43%, p < 0.05). In the SMC subgroup with 2 myopic parents, AL elongation was slowed by 0.18 mm (p < 0.001) while SER progression was slowed by 0.55 D (43%, p < 0.001). SVE reported in a 24-month questionnaire revealed no difference between the SMC and SVL groups. The average daily wearing hours reported in 24 months were similar in the SMC and SVL groups: 14.7 and 14.9 h, respectively.
conclusionAfter 24 months of continuous wear, the SMC lens was proven to be effective in slowing the progression of myopia, especially in children younger than 10 years and in children with two myopic parents. SVE and the prolonged daily use reported by the SMC group indicated good lens tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.